MMP9 and fragile X syndrome: Genetic reduction of MMP-9 in Fmr1 KO mice normalizes PNN formation and prevents the development of neuronal hyperexcitability (Lovelace et al., 2016; Wen et al., 2017), emphasizing the therapeutic potential of targeting MMP-9 and PNN in treatment of FXS.